- FDA Authorizes Use Of COVID-19 Treatment Used With Trump
- The U.S. Food and Drug Administration on Saturday granted an emergency authorization for the antibody treatment presumed by Trump
- This was one of the treatments he received while hospitalized for COVID-19 at Walter Reed National Military Medical Center
A few moments ago it was announced that the United States Food and Drug Administration (FDA) authorized the emergency use of the treatment for COVID-19 from the pharmaceutical company Regeneron.
According to de The Hill, the “Regeneron antibody cocktail” could be used in the treatment of COVID-19 in patients of at least 12 years old, who have a high risk of becoming seriously ill from coronavirus.
Trump and the Regeneron treatment
According to the Efe agency, this treatment with monoclonal antibodies was the one that US President Donald Trump received in October to treat the disease.
The authorization limits use of the drug to people 12 years of age and older who have tested positive for COVID-19 and are at risk of developing a severe case of the disease, FDA chief scientist Denise M. Hinton explained in a letter sent to the company.
The drug is a cocktail of two powerful antibodies that, in preliminary studies, have shown promising results in containing the infection, especially when given during the early stages of the disease.
The FDA already granted another emergency authorization earlier this month for the use in the country of a very similar cocktail, owned by the pharmaceutical company Eli Lilly. Neither treatment can be given to hospitalized people or patients who need oxygen.
Shortly after confirming that he had tested positive for COVID-19 in early October, Trump received an 8-gram dose of Regeneron’s antibody cocktail, even though its use was not cleared by the FDA.
Filed Under: FDA Trump COVID-19 Treatment